SK Biopharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- SK Biopharmaceuticals's estimated annual revenue is currently $1.7B per year.
- SK Biopharmaceuticals's estimated revenue per employee is $455,000
Employee Data
- SK Biopharmaceuticals has 3714 Employees.
- SK Biopharmaceuticals grew their employee count by -41% last year.
SK Biopharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $42.9M | 132 | -7% | N/A | N/A |
#2 | $3.3M | 17 | -6% | N/A | N/A |
#3 | $6.1M | 27 | -21% | N/A | N/A |
#4 | $162.5M | 400 | 16% | N/A | N/A |
#5 | $15.8M | 54 | 0% | N/A | N/A |
#6 | $42.6M | 131 | 8% | N/A | N/A |
#7 | $17.8M | 61 | -14% | N/A | N/A |
#8 | $1.2M | 16 | -11% | $1.3M | N/A |
#9 | $0.3M | 9 | 0% | $25M | N/A |
#10 | $597.9M | 1314 | 23% | N/A | N/A |
What Is SK Biopharmaceuticals?
SK Biopharmaceuticals is a part of the global conglomerate SK Group, the second largest company in Korea. We’re responsible for the development of innovative next-generation drugs within SK Group. SK Biopharmaceuticals has been developing many new drug candidates in the area of CNS, led by the clinical development center(SK Life Science) located in United States and the research center in Pangyo Techno-valley, Gyeonggi-do. With the experience and expertise in the CNS area, SK Biopharmaceuticals will continue to thrive as a successful new drug development company and become a trusted partner through its global R&D network. By 2020, SK Biopharmaceuticals envisions to grow into a global Fully Integrated Pharmaceutical Company (FIPCO) with streamlined capabilities from research to marketing. For more information, visit our website at www.skbp.com.
keywords:N/A
N/A
Total Funding
3714
Number of Employees
$1.7B
Revenue (est)
-41%
Employee Growth %
N/A
Valuation
N/A
Accelerator
SK Biopharmaceuticals News
Ubix Therapeutics, SK Biopharmaceuticals to develop new compounds and medicines through Ubix's Degraducer® technology for cancer treatment.
Cenobamate is an anti-seizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK life science. While the precise...
Axsome will also assume the commitments of Jazz to SK Biopharmaceuticals (SK) and Aerial Biopharma (Aerial). SK is the originator of Sunosi...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $52160M | 3714 | 2% | N/A |
#2 | $1149.1M | 3731 | -2% | N/A |
#3 | $1327.1M | 3732 | 7% | N/A |
#4 | $1423.9M | 3767 | 1% | N/A |
#5 | $1319.2M | 3769 | 6% | N/A |